EPID-09. INCREASED OVERALL SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OVER THE PAST 40 YEARS, EXCEPT IN THE ELDERLY

There has been significant improvement in treatment outcomes of Primary Central Nervous System Lymphoma (PCNSL) at specialized centers over the past several decades. However, it is unclear if these changes have translated to benefits in the general population. In this study, we utilized two national databases to examine incidence and survival trends over time for PCNSL (Central Brain Tumor Registry of the United States (CBTRUS, 2000 – 2013) and 18 Surveillance, Epidemiology and End Results (SEER, 1973 – 2013) registries). The annual incidence of PCNSL in 2013 was 0.4 per 100,000 population (CBTRUS/SEER). Incidence increased from 0.1 per 100,000 in the 1970s to 0.4 per 100,000 in the 1980s, correlating with an increase in the diagnosis of patients ≥70 years (1973:0.2 vs 2013:2.1 – SEER). Incidence rates differed greatly between young and elderly patients (age 20–29 years: 0.08 vs 70–79: 4.32 – CBTRUS). Even though the median overall survival of all patients doubled from 12.5 months in the 1970s to 26 months in the 2010s, this survival benefit was limited to patients <70 years. Survival in the elderly population, ≥70 years, did not change over the last 40 years (6 months in the 1970s vs 7 months in the 2010s, p-value = 0.1). The poor outcome seen in this vulnerable patient population highlights the need for clinical trials targeting the elderly in hopes of improving treatment strategies and survival.